Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial.
Owen A. O'Connor
No relevant relationships to disclose
Tamás Masszi
No relevant relationships to disclose
Kerry J. Savage
No relevant relationships to disclose
Lauren C. Pinter-Brown
Consultant or Advisory Role - Spectrum Pharmaceuticals
Francine M. Foss
Consultant or Advisory Role - Celgene; Eisai; Millennium; Spectrum Pharmaceuticals
Leslie Popplewell
No relevant relationships to disclose
Amanda F. Cashen
Consultant or Advisory Role - Allos Therapeutics
Jeanette Doorduijn
No relevant relationships to disclose
Shanta Chawla
Employment or Leadership Position - Spectrum Pharmaceuticals
Stock Ownership - Spectrum Pharmaceuticals
Poul Knoblauch
Employment or Leadership Position - TopoTarget
Stock Ownership - TopoTarget
Pier Luigi Zinzani
No relevant relationships to disclose
Peter Brown
No relevant relationships to disclose
Georg Hess
No relevant relationships to disclose
Achiel Van Hoof
No relevant relationships to disclose
Steven M. Horwitz
Consultant or Advisory Role - Allos Therapeutics; Bristol-Myers Squibb; Celgene; Genzyme; Janssen-Ortho; Johnson & Johnson; Kyowa Hakko Kirin; Millennium; Seattle Genetics
Research Funding - Allos Therapeutics; Celgene; Infinity; Kyowa Hakko Kirin; Millennium; Seattle Genetics
Andrei R. Shustov
No relevant relationships to disclose